Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = protean agonist

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
8 pages, 219 KiB  
Opinion
Buprenorphine: Far Beyond the “Ceiling”
by Rosmara Infantino, Consalvo Mattia, Pamela Locarini, Antonio Luigi Pastore, Sabatino Maione and Livio Luongo
Biomolecules 2021, 11(6), 816; https://doi.org/10.3390/biom11060816 - 31 May 2021
Cited by 22 | Viewed by 16809
Abstract
Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or [...] Read more.
Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine. Full article
Back to TopTop